Skip to main content

HOW CANCER DEVELOPES IN A NORMAL HUMAN BODY ??






Cancer
which is also known as Carcinoma. There are two terms regarding cancer and these are benign and malignant. Benign cancers are not fatal and these can be cured by treatment like surgery and radiotherapy. But malignant cancers are fatal. Because it can not be cured by treatment due to its spreading nature.

At first there are some stimuli that alters the normal function and growing pattern of a cell. The stimuli are called Carcinogens. Carcinogens are chemical or radiation or something like this. When carcinogens enter into the body repeatedly then it alters the normality of our cells. Then our cells show abnormality in growing and metabolism. At the same time our body tries to compensate this changes. But when fails then this abnormality takes figure into any benign lesion. This benign lesion can be the benign cancer cells in an adenoma ( Its a benign tumor of glandular tissue, like breast ) . Then these benign cells grows more rapidly due to repeated stimuli and finally spreads into other organs via blood streams or lymphatics. This is called metastasis. Metastasis can also occur by seeding through body cavities ( IE. Krukenbeg's Tumour of Overy ). Finally this spreader reside in another tissue of our body and further shows abnormality on that organ.

Now, What is the treatment of these things ? The ultimate goal to treat cancer is in two stages. Number one, is it in benign stage or in malignant stage. If its benign then we can treat it with a radiotherapy. Its nothing but a radioactive ray is given to destroy to those abnormal cells. But if its dissiminated through out the body then we will give the Chemotherapy. Its the chemical drugs that selectively destroyes those cancer cells. In benign stage we can also remove that mass of tumour by a surgery.

Comments

Popular posts from this blog

Artificial pancreas ... an option

Coming Soon: 'Artificial Pancreas' Options for Diabetes Miriam E Tucker June 20, 2016   NEW ORLEANS — Nearly closed-loop systems (also referred to as an "artificial pancreas") for improving glycemic control and minimizing hypoglycemia in type 1 diabetes are advancing rapidly, including iterations that deliver insulin alone, insulin with glucagon, or glucagon alone. Findings for several of the products in development demonstrating improvements in glycemic control and reductions in hypoglycemia were presented here at the  American Diabetes Association (ADA) 2016 Scientific Sessions . "Some people may do well on insulin only, while others may need glucagon," Vincent Crabtree, PhD, director of the artificial pancreas program at JDRF, in New York, told  Medscape Medical News , adding, "JDRF would like people to have choice, and we'd like all to be covered [by payers]." The insulin-only hybrid closed-loop 670G system (Medtronic MiniMed) is the...
Liver Stem Cells Discovered in Mice Share on email Share on facebook Share on twitter Scientists successfully identified and grew a renewable population of liver stem cells for the first time, a new study reported. Tissues derived from these stem cells slightly boosted liver function when implanted into mice with a liver disorder. The findings could eventually lead to approaches that help rejuvenate damaged livers in people. A single cell was coaxed to mature into liver cells that produce common liver proteins (green and red).  Image courtesy of Huch et al.,  Nature . The liver is a large, versatile organ that has many jobs, including cleansing blood and digesting food. The liver also has a unique ability to quickly regenerate and regain its original size if partially removed by surgery. Scientists have long known that stem cells that have the potential to create more liver cells must exist in the adult liver. But until now, no one had found a way to detect a...

Erythropoietin as a Retinal Angiogenic Factor in Proliferative Diabetic Retinopathy

Although vascular endothelial growth factor (VEGF) is a primary mediator of retinal angiogenesis, VEGF inhibition alone is insufficient to prevent retinal neovascularization. Hence, it is postulated that there are other potent ischemia-induced angiogenic factors. Erythropoietin possesses angiogenic activity, but its potential role in ocular angiogenesis is not established. METHODS We measured both erythropoietin and VEGF levels in the vitreous fluid of 144 patients with the use of radioimmunoassay and enzyme-linked immunosorbent assay. Vitreous proliferative potential was measured according to the growth of retinal endothelial cells in vitro and with soluble erythropoietin receptor. In addition, a murine model of ischemia-induced retinal neovascularization was used to evaluate erythropoietin expression and regulation in vivo. RESULTS The median vitreous erythropoietin level in 73 patients with proliferative diabetic retinopathy was significantly higher than that in 71 patients with...